Gilead signs antibiotic development deal with CURx Pharmaceuticals

02/20/2014 | Genetic Engineering & Biotechnology News

Gilead Sciences and CURx Pharmaceuticals agreed to collaborate in the development of a broad spectrum combination antibiotic for the treatment of Pseudomonas aeruginosa lung infection, which affects cystic fibrosis patients. The drug, a combination of antibiotics fosfomycin and tobramycin, is ready to enter late-stage trials after yielding positive results in a midstage study involving CF patients with Pseudomonas aeruginosa infection.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Quality Regulatory Affairs
Cardinal Health
Chicago, IL
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC